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letters containing 655 violations for 204 drugs across multiple therapeutic areas 
were issued by the FDA all of which were clinical. Most often multiple violations 
for > 1 drug were contained in a single letter. On average, ~36 warning letters 
were issued per year. Omission of risk information was the most frequently viola-
tion claim (29.0%) followed by unsubstantiated/overstatement of efficacy claims 
(24.76%), and broadening of indication (11.6%). There were no misleading QoL, or 
economic claims issued. Warning letters were primarily directed to manufactur-
ers of oncology (17.5%), psychiatry (9.6%), cardiovascular (9.6%), and pain (8.8%) 
products. Approximately half (49.5%) of claims contained promotional materials 
directed to physicians. CONCLUSIONS: We found that misleading clinical outcome 
claims, specifically omission of risk information and inaccurate efficacy, formed 
the majority of the promotional violations. Compared to the preceding 6 years 
(2003-2008), substantially more FDA warning letters were issued (65 vs 178) pos-
sibly indicating greater surveillance by the FDA of pharmaceutical promotional 
materials 2009-2013.
PHP35
CHaraCteristiCs of ProduCts witH PriCe CHanges after a PoliCy 
CHange in egyPt
Mohamed O.1, Kreling D.2
1Merck & Co. Inc., Lebanon, NJ, USA, 2School of Pharmacy, Madison, WI, USA
OBJECTIVES: In Egypt, the Ministry of Health and Population (MOHP) sets phar-
maceutical prices from ex-factory to retail. In July 2012, the pricing policy changed 
from a cost plus to an external reference pricing method which was effective in 
October 2012. Our goal was to identify the characteristics of products with price 
changes after the policy implementation. Methods: We used MOHP lists and IMS 
data to pre-identify products with price changes. METHODS: We used MOHP lists 
and IMS data to pre-identify products with price changes. In addition, purchase 
and sales data were obtained from a chain pharmacy in Alexandria for all trans-
actions pre- and post- the policy change (April - Jun 2012 and 2013) to validate 
price changes, assess sales activity, and identify any additional products with 
price changes. Bivariate analysis and a logistic regression model were done to 
identify the determinants of price increase or decrease per Daily Defined Dose 
(DDD). RESULTS: A total of 206 products were subject to price changes; 66% of the 
products had price increase, 70% were generics, 36% were essential drugs, 40% 
of the products had prices less than 1EGP[1]/DDD, 30% were between1 and 5EGP/
DDD and 30% were higher than 5EGP/DDD. Half of the products were produced 
by domestic private companies, 27% by multinational firms, 21% by state-owned 
companies and 2% were imported. The products of state-owned firms had 23 times 
the odds of the products of multinational firms to have a price increase. Similarly, 
the cheapest products had 9 times the odds of a price increase compared to high 
priced products. Compared to brand name drugs, generics had 6.8 times the likeli-
hood of a price increase. CONCLUSIONS: Being the product of State-owned firms, 
a product whose price was ≤ 1EGP/DDD or a generic were the main determinants 
of price increase. [1] 1 EGP= $0.14 USD
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OBJECTIVES: The healthcare profile in sub-Saharan Africa is changing due to eco-
nomic growth, an increasing middle class, urbanization, and rising incidence of 
non-communicable diseases. These factors increase demand for medications. 
Pharmaceutical spending in the region is projected to reach $45 billion by 2016. 
Despite this rapid growth and gap between availability and demand, companies 
have yet to initiate local pharmaceutical manufacturing due to the challenges of 
doing business in the region. We report on a framework to assess these challenges 
and feasibility of overcoming them. METHODS: We undertook a series of key stake-
holder interviews in Namibia, including distribution, private sector, regulatory, and 
governmental representatives. Namibia had virtually no drug manufacturing at 
time of assessment despite political will to undertake manufacturing. RESULTS: 
In-country pharmaceutical manufacturing is viewed as important for health and 
economic development and stability. Key areas identified for concern included 
product selection, education, training, quality control, perceptions of quality, sup-
ply chain, role of public and private sectors, and market demand. Creation of a 
facility at the local university was recommended to build public trust, enhance 
training, and facilitate distribution. Product areas for initial consideration may 
include sterile water/saline, alcohol hand rub, oral preparations, topical prepara-
tions, total parenteral nutrition, or cancer chemotherapy. CONCLUSIONS: In order 
to create a sustainable health care system in sub-Saharan Africa, local pharmaceu-
tical manufacturing will be necessary to provide a consistent supply of medicine. 
Product selection is of key importance to match local demand and be reasonably 
competitive economically. Viable choices could be niche products or large volume 
generics. Regulatory and quality concerns will have to be thoroughly addressed to 
establish a successful system. Technical expertise will have to be increased and 
maintained. Overall, if concerns are addressed early and thoroughly, local manu-
facturing could provide increase political and economic stability in sub-Saharan 
Africa while improving health.
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OBJECTIVES: Considerable attention is given to managing opioid use in order to 
avoid addiction and possible diversion problems. A Pharmacy Quality Alliance work-
group has been working on a pharmacy quality measure where morphine equivalent 
the level of supportive clinical data (Phase 1: a mean of 158 days, Phase 2: 170 days, 
Phase 3: 196 days), whether the drug was a first approval or line extension (175 vs. 
192 days), or whether it was approved under an accelerated FDA pathway or not (172 
vs. 184 days) CONCLUSIONS: The FDA breakthrough therapy designation is proving 
a popular means by which promising drugs can gain patient access on preliminary 
data packages from as little as Phase I supportive data. However, although this 
pathway has enabled earlier access, it does not speed the required review times 
with the average of 6 month review being in line with FDA priority review targets.
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OBJECTIVES: This study analyzes the influence of intellectual property rights pro-
tection on the profile of drug request by litigation in the Health Department of 
Minas Gerais state (SES-MG), Brasil, the public spending and its interfaces with 
the rational use of drugs and the incorporation of new technologies in the Unified 
Health System (SUS). METHODS: This is a descriptive observational study of litiga-
tion by drugs attended by SES-MG. There were analyzed 4,140 records of lawsuits 
in 2010 attended by SES-MG and 1,065 rulings published in the website of the Court 
of Minas Gerais State, in the period from 2007 to 2009. RESULTS: In 2010, SES-MG 
attended 28,104 prescriptions requirement of legalization, the average being 2.2 
medications per patient. The prevalence of polypharmacy was 10.6%. In addition 
to individual lawsuits, the SES-MG attended 19 civil suits which included 135 medi-
cines. The ten most demanded drugs were protected by patents. Of these, only 
three were included on the list of essential medicines. For all products there were 
prescriptions by brand name, an average of 50% of the requests had required supply 
trademark. The survey indicated a prevalence of jurisprudential injunction and the 
use of prescription drugs cited as evidence, without medical expertise. Ensuring the 
constitutional right to health was the speech used in more shares. It was observed 
that the lawsuits are at odds with the rational use of medicines recommended by 
World Health Organization (WHO). CONCLUSIONS: The annual expense to ensure 
access to medicines for litigation is growing and represents a major challenge for 
the public manager. The high prevalence of new medicines prescribed by trademark 
and growth of biological drug prescriptions show the need to review and strengthen 
the policy of generic drugs in Brazil.
PHP33
ComPetition and strategiC regulation in tHe argentine 
PHarmaCeutiCal market. a ComParative study of six tHeraPeutiC 
Classes
Maceira D., Palacios A.
Center for the Study of State and Society (CEDES), Buenos Aires, Argentina
OBJECTIVES: To analyze how main determinants of competition in six therapeutic 
target groups -analgesics, tranquilizers, peptic ulcer treatment, cholesterol treat-
ment, benign prostatic hypertrophy and ACE inhibitors- were affected by regula-
tions and drug policies implemented at national level during the last decade in 
the pharmaceutical market in Argentina. METHODS: The database corresponds 
to the annual information on retail sales in the Argentine pharmaceutical sector 
generated by IMS for the period 2005-2012. The estimation strategy takes the form 
of econometric models of ordinary least squares with year fixed effects and robust 
standard errors. The dependent variables explain the market shares of each product/
brand per therapeutic class, explained by prices, participant active principles, and 
a set of variables capturing product differentiation mechanisms implemented by 
pharmaceutical firms. Each therapeutic class’ regression was exposed to a vector of 
variables capturing the structure of the regulatory framework. RESULTS: In general, 
prices do not show to be significant determinants of market shares, unlike factors 
associated with mechanisms of product differentiation do, proving they facilitate 
the development of brand loyalty and adherence, even with relatively higher prices. 
On the other hand, the inclusion of new active principles in the Compulsory Health 
Program (CHP) will act as a boost for priority prescriptions, while the production 
of generic medicines increases competition, reducing market shares. In addition, 
the impact of these policies rests heavily on the structure of competition in each 
therapeutic class. CONCLUSIONS: The main health policy recommendations sug-
gest: the need to develop new areas of collaboration with the pharmaceutical sector, 
enhancing competition in markets with higher levels of concentration, facilitating 
the evaluation of policies on generic medicines, and successfully regularizing the 
structure of drugs and products available through the CHP.
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OBJECTIVES: While analyses of FDA warning letters issues to pharmaceutical 
companies for misleading promotional outcomes claims have been published for 
1997-2008 (Stewart 2002; Salas 2008; Covington, 2009; Yang 2010; Chatterjee, 2012; 
Neumann 2012), there are no published analyses to date that specifically identify 
the focus of promotional claim violations from 2009-2013. METHODS: Warning let-
ters for promotional materials issued by the FDA to pharmaceutical manufacturers 
from 2009-2013 were downloaded and assessed by two investigators for misleading 
claims broadly classified clinical, quality of life (QoL), and economic. Clinical claim 
violations were then stratified according to the following categories: unsubstanti-
ated efficacy, safety and tolerability, superiority, broadening of indication and/or 
omission of risk information. QoL claims categories included unsubstantiated and/
or health-related (HRQoL). Economic claim categories included cost superiority/ 
savings of one drug compared to another. RESULTS: In the 5-year study period, 178 
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OBJECTIVES: To study the longitudinal trend (between 2000 and 2012) in substance 
use admissions among older adults, i.e., those aged 55 or older. METHODS: Using 
the Treatment Episode Data Set - Admissions (TEDS-A) for the period between 2000 
and 2012, we analyzed the trend in substance use admissions reported for older 
adults. Substance use admissions for older adults as a proportion of total sub-
stance use admissions were compared. Also, the trend in admission for primary 
substances such as cocaine/crack, marijuana/hashish, heroin, non-prescription 
methadone, other opiates and synthetics, methamphetamine, and benzodiazepines 
was compared. RESULTS: Of the total admissions for substance use in 2000, 3.4 
percent were attributable to older adults. Over time, there was a increase in this 
proportion and in 2012, 7.0 percent of all substance use admissions were accounted 
for by older adults. Older adults also exhibited sharp escalation in proportion of 
admissions between 2000-2012 where primary substance that led to admission 
was cocaine/crack (63% increase), marijuana/hashish (150% increase ), heroin (26% 
increase), non-prescription methadone (200% increase), other opiates and synthet-
ics (221% increase), methamphetamine (275% increase), and benzodiazepines (67% 
increase). CONCLUSIONS: It is important to note that though the total number of 
substance use admissions between 2000 and 2012 changed only a little, the propor-
tion of admissions attributable to older adults increased greatly. Among older adults, 
substance use is an important psychosocial co-comorbidity. Admissions for certain 
types of substances appear to be on the rise . Presence of substance use translates 
into treatment need. It can affect health outcomes and complicate management 
of other co-morbid conditions. Therefore, a surge in substance use in older persons 
coupled with aging of the US population has substantial implications for the entire 
healthcare system. There is an urgent need for appropriate preventive and treat-
ment polices aimed specifically towards older adults with a substance use disorder.
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OBJECTIVES: Analysis of the consumption of antibiotics plays a very important 
role in hospital care, since it allows the identification of areas where measures to 
improve the suitability for use and rationalization of resources should be adopted, 
stimulating improve the quality and development of surveillance strategies anti-
biotic resistance. The consumption of antibiotics in Slovak hospitals is still high 
compared with the other European countries. The aim of the study was to analyze 
the utilisation of antibiotics in the hospital sector in Slovakia. METHODS: Drug’s 
expenditure derived from the State Institute of Drug Control. Antibiotic drug con-
sumption was expressed as number of packages and as DDDs per 1000 inhabitants 
per day (DID). Data were analyzed according to ATC classification. RESULTS: During 
the period 2011 – 2014 was increased consumption of antibiotics - expressed as 
number of packages - in the ATC group J01D, in the community sector (primary 
care sector). By contrast, in the hospital pharmacies, the consumption gradually 
decreases. The Macrolides (J01F), one of the most prescribed antibiotics in commu-
nity sector reach 30% of the total volume consumed antibiotics in the community, 
in hospital sector but only 5%. While consumption of penicillins in hospital sector is 
increasing slightly (5% during the period), in the group of other beta-lactam antibiot-
ics, decrease (10 % during the period). CONCLUSIONS: According of the antibiotics 
costs demonstrated the development of consumption during the analyzed period 
decreasing trend. The decreasing consumption of antibiotics in community sector 
leads to increase of consumptions in hospital sector. The other analysis of consump-
tion at the hospital level should help health care providers to improve antibiotic use.
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OBJECTIVES: Drug-related problems (DRPs), prescribing pattern (PP) and poly-
pharmacy are identified as important risk factors in pharmaceutical care plan-
ning. This study was aimed to evaluate DRPs, PP and poly pharmacy issues in 
Pakistan. METHODS: A drug utilization-pattern regarding DRPs, PP and polyphar-
macy was evaluated at filling and refilling of the prescriptions written by registered 
medical practitioners and specialized physicians at local community pharmacies’ 
in a province, the Punjab, Pakistan. A stratified sample manner was adopted for 
selecting different community pharmacies. All of the prescriptions were ana-
lyzed according to WHO standard treatment guidelines for DRPs, PP and polyp-
harmacy. RESULTS: Among 900 observed prescriptions from different cities of the 
province, several DRPs, vague PP and polypharmacy issues were observed. Unfair 
numbers and types of drugs than the WHO recommendations were prescribed for 
each patient. Mean number of drugs in a single prescription were 5.0 (+1.6). The 
worth of prescribing indicators was much more than the WHO standard indica-
tors. A significant number of medicines (89%) were written in their brand names. 
Furthermore, the repeatedly prescribed medicines were antibiotics (55.1%), anxiolyt-
ics (22.4%), and corticosteroids (26%). CONCLUSIONS: Physicians’ adherence to the 
WHO standard prescribing guidelines was poor. Effecting apposite administrative 
dosing would be used to identify potential problem cases. The objective of this 
study was to evaluate the criteria being discussed by in this potential measure in 
Mississippi Medicaid. METHODS: A retrospective study was done using Mississippi 
Medicaid claims data for 2013. Beneficiaries were included if enrolled the entire 
year, had 1+ prescription for an opioid in the Center for Disease Control Morphine 
Milligram Equivalent Table, were age 19+, and they did not have any claims with 
diagnoses of sickle cell anaemia or cancer, were not dual eligible or in long term 
care. Morphine Equivalent Dose (MED) values were calculated for all prescriptions. 
Cut-off values of 120mg and 100mg MED were examined with sensitivity analysis 
for number of days at or above the cut-off. RESULTS: 1.37% and 2.24% of the benefi-
ciaries received prescriptions for opioids > 100mg MED for ≥ 60 and 30≥ consecutive 
days. 1.72% and 2.70% of the beneficiaries were found to receive prescriptions of 
opioids > 120mg MED for ≥ 60 and 30≥ consecutive days. Approximately, 1.77% of 
beneficiaries having an opioids prescription claims are consuming an MED greater 
than 120mg for more than 31 days indicating issues with their opioid consump-
tion pattern. 12.5% of beneficiaries having > 100mg MED for 30+ consecutive days 
were doctor shopping (using 4+ pharmacies and 4+ prescribers). CONCLUSIONS: 
Beneficiaries with high MED are at risk of becoming abusers, if they are not already. 
Use of MED limits in drug utilization review is a good method for identifying ben-
eficiaries at risk of becoming abusers. Combining doctor shopping with high MED 
can be used to identify potential abusers for intervention.
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OBJECTIVES: Bioequivalence studies are required for approval of generic medica-
tions and are regarded as a reliable methodology to evaluate equivalence of generic 
vs. branded products. However, recent issues with a few newly-launched generics 
highlight the need for post-marketing monitoring of generic medicines. Real world 
evidence uniquely available in pharmacy claims data can provide early detection of 
bioequivalence issues well before conventional methods (i.e. MedWatch).This study 
presents an analytic approach that uses pharmacy claims data to monitor possible 
bioequivalence issues with one generic version of the anti-depressant bupropion 
that was finally withdrawn from the market after studies failed to show bioequiva-
lence with the branded product. METHODS: Patient-level pharmacy claims data 
from Express Scripts, a pharmacy benefit manager (PBM) with over 90 million 
Americans, was used in a retrospective study evaluating patient persistence before 
discontinuation. Persistence was defined as the days from medication initiation to 
an instance of 45 days without therapy. Evaluations were done separately for 150 
and 300 mg bupropion and by manufacturer. RESULTS: With the 300 mg bupropion 
where bioequivalence was questioned, the percent of patients non-persistent at day 
360 was notably higher for some generic versions than for others. Manufacturer-
specific drop off rates were more similar for the 150 mg version where bioequiva-
lence was not questioned. Declining persistency among other generic providers 
was also observed, and could be due to awareness of the bioequivalence concerns 
among health professionals. CONCLUSIONS: The results demonstrate a decline 
in utilization of a specific generic anti-depressant medication that subsequently 
failed bioequivalence testing, supporting the use of large PBM claims databases with 
access to real-time product utilization details. Leveraging consumer information 
early in the generic launch process can provide insights into bioequivalence leading 
to improved patient care through early detection and enhance Health Economic and 
Outcomes Research (HECOR) and Market Researcher Post Launch strategy.
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OBJECTIVES: Just over 7 million Americans enrolled in private insurance through 
the new health insurance exchanges in 2014. The exchange plans are required to 
cover essential health benefits, including prescription drugs, although the generos-
ity of prescription drug coverage in exchange plans has not been well described, 
nor compared to employer-sponsored insurance. METHODS: We examined the 27 
federally facilitated exchanges and 7 partnership exchanges, for which character-
istics of all plans on the exchanges were publicly available from data.gov for 2014. 
For comparison we also provide additional results for the 2015 plans. We com-
pared the exchanges with data from the Kaiser Family Foundation/Health Research 
Educational Trust’s annual employer survey. Descriptive analyses of exchange plans 
quantifying plan characteristics including extent of copayments or coinsurance, 
number of pharmacy benefit tiers, average copayment/coinsurance in each for-
mulary tier, and deductible amounts. RESULTS: Within the exchanges, we find 
wide variation in the out-of-pocket costs enrollees will face for generic, preferred 
brand, non-preferred brand and specialty drugs, both across metal tiers and across 
plan type within metal tier. Coinsurance is used instead of copayments for many 
drugs in the upper pharmacy formulary tiers (e.g. Specialty drugs). Compared to 
employer sponsored plans, these exchange plans generally have lower premiums, 
but provide less generous coverage. Cost sharing subsidies for low income indi-
viduals may mitigate the higher out of pocket costs found in many silver exchange 
plans. CONCLUSIONS: On average, exchange plans had lower premiums than 
employer-sponsored insurance plans, but higher deductibles and cost sharing for 
prescription drugs. The gold and platinum-level PPO plans were more generous 
than employer-sponsored coverage on average. Decision tools to assist consumers 
in selecting plans on more attributes than just premium will also be key in helping 
individuals avoid high out of pocket burdens.
